Pages

▼

Monday, 11 July 2011

Grape-flavoured Lipitor gets the go-ahead for children

The Financial Times reported yesterday that pharma giant Pfizer could earn an estimated US$800m following the grant of a six-month paediatric extension to its top-selling drug Lipitor. The children's version is described as "a chewable grape-flavoured low-dose version" which will be launched when its patents expire in November.

The Financial Times article goes on to discuss its assessment of the market value of Lipitor, which currently accounts for one-fifth of Pfizer's sales.

Source: "Pfizer gets $800m boost for Lipitor", Andrew Jack, 10 July 2011
at

1 comment:

  1. Anonymous17 January 2012 at 14:43

    I've just noticed that in September 2011, Dr. Reddy’s Laboratories (UK) Limited filed for revocation of this extension in the High Court.

    ReplyDelete